Coverage would include diagnostic testing to determine appropriate treatments, as well as prescribed treatments or ...
Alzheimer’s disease, the most common form of dementia, affects millions of people worldwide, slowly robbing them of their ...
A decade ago, researchers introduced a new model for studying Alzheimer's disease. Known as "Alzheimer's in a dish," the model uses cultures of mature brain cells suspended in a gel to recapitulate ...
A recent study from the University of California, San Diego, has found a troubling link between certain commonly used ...
Hosted on MSN1d
Nasal spray drug could revolutionize Alzheimer's treatmentA potential new treatment for Alzheimer’s disease may come in the form of a nasal spray. Researchers in Italy have discovered ...
Thanksgiving travel is a must for millions of Americans, but those plans will be complicated for some because they’re ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...
Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated ...
Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...
Cassava Sciences announced that the phase 3 trial of its Alzheimer's drug, simufilam, did not meet its primary endpoints.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback